When was Epirium Bio founded?

Epirium Bio was founded in 2008 and raised its 1st funding round 11 years after it was founded.

Where is Epirium Bio located?

Epirium Bio is headquartered in San Diego, United States.

How many employees does Epirium Bio have?

As of Aug 31, 2026, the latest employee count at Epirium Bio is 13.

Is Epirium Bio a funded company?

Epirium Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 18, 2019.

When was the latest funding round of Epirium Bio?

Epirium Bio's latest funding was a $***** Series A round on Dec 18, 2019, with participation from 6 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $919M in funding in 2026 to date.

Where does Epirium Bio rank among its competitors?

Epirium Bio ranks 94th amongst 711 active competitors, of which 206 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Epirium Bio?

Epirium Bio's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Epirium Bio - 2026 Company Profile, Funding & Competitors

Epirium Bio is a series A company based in San Diego (United States), founded in 2008. It operates as a Developer of therapeutic solutions for the treatment of cancer patients. Epirium Bio has raised $85M in funding from Arch Venture Partners and Longitude Capital. The company has 711 active competitors, including 206 funded and 160 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Epirium Bio is a developer of therapeutic solutions for the treatment of cancer patients. It is developing viral immunotherapies that promote mitochondrial biogenesis and function. The company is developing for cancer patients. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and function.

Website: epirium.com
Email ID: *****@epirium.com

Key Metrics

Founded Year

2008

Location

San Diego, United States

Stage

Series A

Total Funding

$85M in 1 round

Latest Funding Round

Series A, Dec 18, 2019, $*****

Investors

Arch Venture Partners & 6 more

Ranked

94^th among 711 active competitors

Employee Count

13 as on Aug 31, 2026

Similar Companies

Biogen & 116 more

View Epirium Bio's full profile

Epirium Bio has raised a total funding of $85M over 1 round. Its latest funding round was a Series A round on Dec 18, 2019 for $*****. 6 investors participated in its latest round. Epirium Bio has 7 institutional investors.

Here is the list of recent funding rounds of Epirium Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 18, 2019	3400651	Series A	2347587	4502439	3598854	5973303

Access funding benchmarks and valuations. Sign up today!

View details of Epirium Bio's funding rounds and investors

Epirium Bio's employee count trend

Epirium Bio has 13 employees as of Aug 26. Here is Epirium Bio's employee count trend over the years:

Uncover Epirium Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epirium Bio include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Epirium Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 7 others	69/100
6th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
7th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
8th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100
9th	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
10th	Cytokinetics 1997, San Francisco (United States), Public	Developer of muscle activators as potential treatments for debilitating diseases	$60M	Vulcanventuresinvestments.com, Amgen Business Development ... & 12 others	68/100
94th	Epirium Bio 2008, San Diego (United States), Series A	Developer of therapeutic solutions for the treatment of cancer patients	$85M	Adams Street Partners, Longitude Capital & 5 others	54/100